Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 7/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | PDE2A | O00408 | 7/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12609669 | 1.00 | DRD3 (0.44) | DRD3USP30PDE2A | |
| SCHEMBL14151172 | 1.00 | DRD3 (0.44) | DRD3USP30PDE2A | |
| SCHEMBL14151252 | 0.87 | DRD3 (0.41) | DRD3USP30PDE2A | |
| SCHEMBL14151988 | 0.87 | DRD3 (0.41) | DRD3USP30PDE2A | |
| SCHEMBL14151249 | 0.87 | DRD3 (0.41) | DRD3USP30PDE2A | |
| SCHEMBL14150820 | 0.85 | DRD3 (0.41) | DRD3USP30PDE2A | |
| SCHEMBL18421080 | 0.85 | DRD3 (0.41) | DRD3USP30PDE2A | |
| SCHEMBL12609752 | 0.85 | DRD3 (0.41) | DRD3USP30PDE2A | |
| SCHEMBL14150776 | 0.85 | DRD3 (0.41) | DRD3USP30PDE2A | |
| SCHEMBL16986594 | 0.85 | DRD3 (0.41) | DRD3USP30PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688870-B1 | HETEROCYCLIC AMINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-02-01 | — | — | EP | disclosed |
| EP-2718271-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-9029370-B2 | Substituted benzamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-8802673-B2 | Heterocyclic amine derivatives | Hoffmann-La Roche Inc (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2718271-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| EP-2688870-A1 | HETEROCYCLIC AMINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-29 | — | — | EP | disclosed |
| WO-2012168265-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120316165-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-12-13 | — | — | US | disclosed |
| WO-2012126922-A1 | HETEROCYCLIC AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-27 | — | — | WO | disclosed |
| US-20120245172-A1 | HETEROCYCLIC AMINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245172-A1 | HETEROCYCLIC AMINE DERIVATIVES | TAAR1, TAAR5, MTNR1A | DRD3 583/4885USP30 4358/4885PDE2A 758/4885 |
| US-20120316165-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | NPY4R, PER2, NPY1R | DRD3 164/4885USP30 4247/4885PDE2A 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.